Association of smoking with myocardial injury and clinical outcome in patients undergoing mechanical reperfusion for ST-elevation myocardial infarction

European Heart Journal Cardiovascular Imaging

Volumn 18, Issue 1, 2017, Pages 39-45

  Reinstadler, Sebastian J ^a,b,c   Eitel, Charlotte ^a,b   Fuernau, Georg ^a,b   Dewaha, Suzanne ^a,b   Desch, Steffen ^a,b   Mende, Meinhard ^d   Metzler, Bernhard ^c   Schuler, Gerhard ^d   Thiele, Holger ^a,b   Eitel, Ingo ^a,b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Magnetic resonance imaging; Prognosis; Smoker's paradox; Smoking; St elevation myocardial infarction

Indexed keywords

ABCIXIMAB;

ADULT; AGED; ARTICLE; BLEEDING; BODY WEIGHT; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CLINICAL OUTCOME; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; GROUPS BY AGE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE INJURY; HEART RATE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; INTRAMYOCARDIAL HEMORRHAGE; MAJOR ADVERSE CARDIAC EVENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTICENTER STUDY (TOPIC); MYOCARDIAL SALVAGE INDEX; NUCLEAR MAGNETIC RESONANCE SCANNER; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTOLIC BLOOD PRESSURE; TIME TO TREATMENT; CARDIAC MUSCLE; CINE MAGNETIC RESONANCE IMAGING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; ELECTROCARDIOGRAPHY; FOLLOW UP; HEART MUSCLE REPERFUSION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; ST ELEVATION MYOCARDIAL INFARCTION; SURVIVAL RATE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; MYOCARDIAL REPERFUSION; MYOCARDIUM; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SMOKING; ST ELEVATION MYOCARDIAL INFARCTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 85019683333     PISSN: 20472404     EISSN: 20472412     Source Type: Journal    
DOI: 10.1093/ehjci/jew030     Document Type: Article

References (37)

1. Barua RS, Ambrose JA. Mechanisms of coronary thrombosis in cigarette smoke exposure. Arterioscler Thromb Vasc Biol 2013;33:1460-7.
2. Molstad P. First myocardial infarction in smokers. Eur Heart J 1991;12:753-9.
3. Kelly TL, Gilpin E, Ahnve S, Henning H, Ross J Jr. Smoking status at the time of acute myocardial infarction and subsequent prognosis. Am Heart J 1985;110:535-41.
4. Barbash GI, White HD, Modan M, Diaz R, Hampton JR, Heikkila J et al. Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Circulation 1993;87:53-8.
5. Barbash GI, Reiner J, White HD, Wilcox RG, Armstrong PW, Sadowski Z et al. Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the 'smoker's paradox' from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1995;26:1222-9.
6. Grines CL, Topol EJ, O'Neill WW, George BS, Kereiakes D, Phillips HR et al. Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction. Circulation 1995;91:298-303.
7. Gourlay SG, Rundle AC, Barron HV. Smoking and mortality following acute myocardial infarction: Results from the National Registry of Myocardial Infarction 2 (NRMI 2). Nicotine Tob Res 2002;4:101-7.
8. Ruiz-Bailen M, de Hoyos EA, Reina-Toral A, Torres-Ruiz JM, Alvarez-Bueno M, Gomez Jimenez FJ et al. Paradoxical effect of smoking in the Spanish population with acute myocardial infarction or unstable angina: Results of the ARIAM Register. Chest 2004;125:831-40.
9. Albertal M, Cura F, Escudero AG, Thierer J, Trivi M, Padilla LT et al. Mechanism involved in the paradoxical effects of active smoking following primary angioplasty: A subanalysis of the protection of distal embolization in high-risk patients with acute myocardial infarction trial. J Cardiovasc Med 2008;9:810-2.
10. Katayama T, Iwasaki Y, Yamamoto T, Yoshioka M, Nakashima H, Suzuki S et al. [Smoker's paradox in patients with acute myocardial infarction receiving primary coronary intervention]. J Cardiol 2006;48:193-200.
11. Verouden NJ, Haeck JD, Kuijt WJ, Meuwissen M, Koch KT, Henriques JP et al. Clinical and angiographic predictors of ST-segment recovery after primary percutaneous coronary intervention. Am J Cardiol 2010;105:1692-7.
12. Wakabayashi K, Romaguera R, Laynez-Carnicero A, Maluenda G, Ben-Dor I, Sardi G et al. Impact of smoking on acute phase outcomes of myocardial infarction. Coron Artery Dis 2011;22:217-22.
13. Gottlieb S, Boyko V, Zahger D, Balkin J, Hod H, Pelled B et al. Smoking and prognosis after acute myocardial infarction in the thrombolytic era (Israeli Thrombolytic National Survey). J Am Coll Cardiol 1996;28:1506-13.
14. Maggioni AP, Piantadosi F, Tognoni G, Santoro E, Franzosi MG. Smoking is not a protective factor for patients with acute myocardial infarction: The viewpoint of the GISSI-2 Study. G Ital Cardiol 1998;28:970-8.
15. Andrikopoulos GK, Richter DJ, Dilaveris PE, Pipilis A, Zaharoulis A, Gialafos JE et al. In-hospital mortality of habitual cigarette smokers after acute myocardial infarction; the 'smoker's paradox' in a countrywide study. Eur Heart J 2001;22:776-84.
16. Weisz G, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G et al. Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction-The smoker's paradox revisited. Am Heart J 2005;150:358-64.
17. Allahwala UK, Murphy JC, Nelson GI, Bhindi R. Absence of a 'smoker's paradox' in field triaged ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention. Cardiovasc Revasc Med 2013;14:213-7.
18. Arbel Y, Matetzky S, Gavrielov-Yusim N, Shlezinger M, Keren G, Roth A et al. Temporal trends in all-cause mortality of smokers versus non-smokers hospitalized with ST-segment elevation myocardial infarction. Int J Cardiol 2014;176:171-6.
19. Shemirani H, Tafti FD, Amirpour A. Comparison of no-reflow phenomenon after percutaneous coronary intervention for acute myocardial infarction between smokers and nonsmokers. J Res Med Sci 2014;19:1068-73.
20. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000;343:1445-53.
21. Friedrich MG, Abdel-Aty H, Taylor A, Schulz-Menger J, Messroghli D, Dietz R. The salvaged area at risk in reperfused acute myocardial infarction as visualized by cardiovascular magnetic resonance. J Am Coll Cardiol 2008;51:1581-7.
22. Eitel I, deWaha, S, Wohrle J, Fuernau G, Lurz P, Pauschinger M et al. Comprehensive prognosis assessment by CMR imaging after ST-segment elevation myocardial infarction. J Am Coll Cardiol 2014;64:1217-26.
23. Eitel I, Desch S, Fuernau G, Hildebrand L, Gutberlet M, Schuler G et al. Prognostic significance and determinants of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. J Am Coll Cardiol 2010;55:2470-9.
24. Klug G, Mayr A, Schenk S, Esterhammer R, Schocke M, Nocker M et al. Prognostic value at 5 years of microvascular obstruction after acute myocardial infarction assessed by cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012;14:46.
25. Thiele H, Wohrle J, Neuhaus P, Brosteanu O, Sick P, Prondzinsky R et al. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial. Am Heart J 2010;159:547-54.
26. Thiele H, Wohrle J, Hambrecht R, Rittger H, Birkemeyer R, Lauer B et al. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: A randomised trial. Lancet 2012;379:923-31.
27. Eitel I, Wohrle J, Suenkel H, Meissner J, Kerber S, Lauer B et al. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: cardiac magnetic resonance substudy of the AIDA STEMI trial. J Am Coll Cardiol 2013;61: 1447-54.
28. Desch S, Engelhardt H, Meissner J, Eitel I, Sareban M, Fuernau G et al. Reliability of myocardial salvage assessment by cardiac magnetic resonance imaging in acute reperfused myocardial infarction. Int J Cardiovasc Imaging 2012;28:263-72.
29. Eitel I, Kubusch K, Strohm O, Desch S, Mikami Y, deWaha, S et al. Prognostic value and determinants of a hypointense infarct core in T2-weighted cardiac magnetic resonance in acute reperfused ST-elevation-myocardial infarction. Circ Cardiovasc Imaging 2011;4:354-62.
30. Eitel I, Desch S, de Waha, S, Fuernau G, Gutberlet M, Schuler G et al. Long-Term prognostic value of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. Heart 2011;97:2038-45.
31. Tibshirani R. The LASSO method for variable selection in the Cox model. Stat Med 1997;16:385-95.
32. Park HW, Yoon CH, Kang SH, Choi DJ, Kim HS, Cho MC et al. Early-And late-Term clinical outcome and their predictors in patients with ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction. Int J Cardiol 2013;169:254-61.
33. Stone PH, Raabe DS, Jaffe AS, Gustafson N, Muller JE, Turi ZG et al. Prognostic significance of location and type of myocardial infarction: independent adverse outcome associated with anterior location. J Am Coll Cardiol 1988;11:453-63.
34. Sorajja P, Gersh BJ, Cox DA, McLaughlin MG, Zimetbaum P, Costantini C et al. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J 2007;28:1709-16.
35. De Luca, G, Dirksen MT, Spaulding C, Kelbaek H, Schalij M, Thuesen L et al. Impact of hypertension on clinical outcome in STEMI patients undergoing primary angioplasty with BMS or DES: insights from the DESERT cooperation. Int J Cardiol 2014; 175:50-4.
36. Klug G, Metzler B. Assessing myocardial recovery following ST-segment elevation myocardial infarction: short-And long-Term perspectives using cardiovascular magnetic resonance. Expert Rev Cardiovasc Ther 2013;11:203-19.
37. Aune E, Roislien J, Mathisen M, Thelle DS, Otterstad JE. The 'smoker's paradox' in patients with acute coronary syndrome: A systematic review. BMC Med 2011;9:97.